Cypherpunk secures a $46M Zcash gain and turns a $4.7M operating loss into $39.4M profit
The Zcash treasury company had $7.6 million in cash as its biotech subsidiary began seeking resources for Phase 3.
Quick Take
- Cypherpunk reported $39.4 million in Q2 net income, reversing a $16.6 million loss after a $46 million ZEC unrealized gain.
- The profit came despite a $4.7 million operating loss, showing ZEC revaluation can outweigh losses without token sales.
- Its biotech arm Leap is seeking resources for sirexatamab Phase 3, but financing or a deal is not assured.
Zcash treasury firm and Leap Therapeutics owner, Cypherpunk Technologies, reported $39.4 million in second-quarter net income, reversing a $16.6 million loss a year earlier.
Cypherpunk recorded a $4.7 million operating loss, while a $46 million unrealized gain on its ZEC treasury drove the change in its bottom line.
Research and development expense accounted for $0.2 million of the quarter’s costs, while general and administrative expense was $4.5 million. That left the company loss-making at the operating level before the ZEC revaluation was reflected in the income statement.
The accounting treatment recognizes price movements without requiring Cypherpunk to sell the tokens.
The $46 million gain was a period-end accounting result, and Cypherpunk marks its Zcash holdings to market at each reporting date. It used a ZEC price of $400.09 at June 30, valuing the treasury at $129.4 million on its balance sheet.
Cypherpunk said it held 323,394.38 Zcash as of Aug. 11 at an average purchase price of $341.83, which is approximately 1.92% of the circulating supply. That average implies an aggregate acquisition cost of roughly $110.5 million.
ZEC traded at $489.34 on CoinGecko at 11:27 UTC on Aug. 12, putting the holdings at approximately $158.2 million.
Cypherpunk reported $7.6 million in cash and cash equivalents as of June 30, separate from the ZEC balance it classified as a digital asset receivable. The quarter shows how the company’s earnings can be shaped by the price used to revalue its treasury.
The cash figure sits alongside a separate decision in Cypherpunk’s biotechnology business. Its wholly owned biotech subsidiary, Leap Therapeutics, initiated a process to secure the resources needed to advance sirexatamab into Phase 3 development.
Leap said the process could include financing the program as an independent entity or pursuing a transaction with a pharmaceutical or biotechnology company. The alternatives include a partnership, a license, a collaboration, a sale, or another business combination.
Cypherpunk set no timetable and cautioned that financing or a transaction was not assured, and it did not link Leap’s resource search to the Zcash strategy.
For investors, the immediate picture is a profitable quarter dominated by an unrealized token gain, alongside a drug program whose next stage still depends on securing additional resources.
Zcash is +2.07% over the past 24 hours and currently sits at rank #12 by market cap.
More Zcash market context Supply, launch date, volume flow, and price-cycle context.
Where the broader market sits right now
Right now, the total crypto market is valued at $2.17T with $53.71B in 24-hour volume. Bitcoin dominance sits at 58.53%. Explore the market
Zcash fixed the flaw that nearly halved ZEC, and $926 million in leverage now tests the rebound
Zcash’s Ironwood upgrade puts ZEC’s $500 recovery against $926 million in open interest and the risk of a derivatives-led reversal.
AI-assisted Zcash flaw exposes the supply integrity gap an emergency fork could not fully close
The AI-assisted discovery of a critical Orchard flaw shows crypto’s next security crisis may start in the base-layer systems that define valid money.
Zcash loses over $5 billion after AI finds 4-year bug that could have created fake hidden coins
Zcash developers say the flaw was patched before any known exploit, but the selloff shows how fragile trust can be around money built to stay private.
Bitcoin miner HIVE’s $79M quarter runs into an $80M Swedish tax problem
Preliminary revenue reached about $79 million, yet HIVE cannot quantify the possible noncash accrual or its expected losses.
Tron Inc. put over 90% of assets behind an uninsured JustLend dependency as its TRX treasury kept growing
About 95% of assets are invested in or committed to TRX, with nearly $230 million routed through JustLend for staking yield.
After selling 832 BTC to clear debt, this Nasdaq-listed crypto firm is using a 1-for-50 reverse split to mask its shrinking treasury
The proposed reverse split can address the $1 bid-price rule, but it cannot replace operating cash.